CRBU
Caribou Biosciences Inc
0.4602$
-4.4%
vs. previous close
Closing price · As of: Oct 9, 2026
Statements
Cash Flow
Caribou Biosciences Inc (CRBU) by the numbers: income statement, balance sheet and cash flow, by year or by quarter. In the most recent period (Q2 26), "Operating Cash Flow" came in at -23 million USD. Tick rows to compare them in a chart.
All figures in millions of USD.
Tick rows to compare them in a chart (up to 4)
| Line item | Q1 20 | Q2 20 | Q3 20 | Q4 20 | Q1 21 | Q2 21 | Q3 21 | Q4 21 | Q1 22 | Q2 22 | Q3 22 | Q4 22 | Q1 23 | Q2 23 | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -9.2 | -7.2 | -8.7 | -8.1 | 20 | -16 | -15 | -21 | -22 | -22 | -22 | -25 | -28 | -15 | -29 | -21 | -37 | -33 | -33 | -35 | -37 | -28 | -25 | -21 | -27 | -23 | -96 | |
| 0.2 | 0.2 | 0.2 | 0.2 | 0.2 | 0.2 | 0.3 | 0.3 | 0.3 | 0.4 | 0.5 | 0.5 | 0.6 | 0.6 | 1.6 | 0.7 | 0.7 | 0.9 | 1.2 | 1.2 | 1.2 | 1.2 | 0.6 | 0.7 | 0.6 | 0.6 | 2.6 | |
| 0.2 | 0.3 | 0.2 | 0.2 | 0.3 | 0.6 | 0.9 | 1.6 | 3.0 | 2.9 | 2.7 | 3.1 | 3.1 | 3.6 | 3.5 | 3.6 | 4.0 | 4.7 | 4.1 | 3.9 | 3.9 | 3.1 | 2.9 | 2.7 | 2.4 | 2.5 | 11 | |
| 1.4 | -7.2 | 0.2 | – | 1.0 | 0.5 | 3.3 | -0.5 | 3.0 | 2.9 | 4.5 | 3.1 | 3.1 | 3.6 | – | – | – | – | – | – | – | – | – | – | – | – | – | |
| -1.1 | 1.7 | -1.2 | 0.8 | 32 | -2.9 | 2.4 | -3.0 | -5.1 | 1.7 | -0.7 | -0.1 | -2.4 | 12 | -22 | 5.0 | -0.8 | 2.9 | -2.8 | -4.3 | -1.5 | 0.6 | -1.4 | 1.9 | -5.0 | -1.9 | -6.4 | |
| 0.6 | 0.1 | 0.0 | 0.6 | 0.0 | 0.5 | 0.9 | 0.7 | 0.7 | 2.6 | 1.7 | 2.1 | 2.0 | 2.6 | 4.8 | 2.3 | 2.9 | 2.4 | 0.7 | 0.5 | 1.0 | 0.4 | 0.1 | 0.2 | 0.1 | 0.0 | 0.4 | |
| 7.0 | -0.1 | 0.0 | -0.6 | 0.0 | -0.5 | -1.9 | -174 | -72 | -14 | -8.3 | 1.2 | 21 | 11 | -68 | -31 | 23 | 21 | 27 | 16 | 49 | 24 | 11 | 18 | 24 | 19 | 72 | |
| – | – | – | – | – | – | – | – | 1.0 | – | – | – | 1.1 | 17 | – | 0.0 | 0.7 | – | -0.7 | – | – | – | – | – | – | – | – | |
| 0.0 | 1.6 | 0.0 | – | -0.1 | 1.2 | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | |
| 0.0 | 1.6 | 0.1 | 0.1 | 110 | 0.6 | 323 | 0.5 | 1.0 | 0.4 | 0.7 | 0.1 | 1.6 | 18 | 135 | 0.0 | 12 | 0.1 | 0.2 | 3.9 | 0.5 | 0.0 | 0.3 | 4.1 | 2.7 | 18 | 25 | |
| -2.3 | -5.7 | -8.6 | -8.6 | 130 | -16 | 306 | -195 | -93 | -35 | -30 | -24 | -5.6 | 13 | 38 | -53 | -1.8 | -12 | -5.9 | -16 | 13 | -4.2 | -14 | 1.2 | -0.3 | 14 | 0.9 | |
| -9.9 | -7.3 | -8.7 | -8.7 | 20 | -17 | -16 | -22 | -22 | -24 | -24 | -27 | -30 | -18 | -34 | -24 | -40 | -35 | -33 | -36 | -38 | -29 | -25 | -21 | -27 | -23 | -96 |
LTM = last twelve months (sum of the four most recent quarters).
Data as of: October 9, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.